Original Article
Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy
N Engl J Med 1998; 338:1785-1792June 18, 1998
- Abstract
Background
Non–Q-wave myocardial infarction is usually managed according to an “invasive” strategy (i.e., one of routine coronary angiography followed by myocardial revascularization).
Methods
We randomly assigned 920 patients to either “invasive” management (462 patients) or “conservative” management, defined as medical therapy and noninvasive testing, with subsequent invasive management if indicated by the development of spontaneous or inducible ischemia (458 patients), within 72 hours of the onset of a non–Q-wave infarction. Death or nonfatal infarction made up the combined primary end point.
Results
During an average follow-up of 23 months, 152 events (80 deaths and 72 nonfatal infarctions) occurred in 138 patients who had been randomly assigned to the invasive strategy, and 139 events (59 deaths and 80 nonfatal infarctions) in 123 patients assigned to the conservative strategy (P=0.35). Patients assigned to the invasive strategy had worse clinical outcomes during the first year of follow-up. The number of patients with one of the components of the primary end point (death or nonfatal myocardial infarction) and the number who died were significantly higher in the invasive-strategy group at hospital discharge (36 vs. 15 patients, P=0.004, for the primary end point; 21 vs. 6, P=0.007, for death), at one month (48 vs. 26, P=0.012; 23 vs. 9, P=0.021), and at one year (111 vs. 85, P=0.05; 58 vs. 36, P=0.025). Overall mortality during follow-up did not differ significantly between patients assigned to the conservative-strategy group and those assigned to the invasive-strategy group (hazard ratio, 0.72; 95 percent confidence interval, 0.51 to 1.01).
Conclusions
Most patients with non–Q-wave myocardial infarction do not benefit from routine, early invasive management consisting of coronary angiography and revascularization. A conservative, ischemia-guided initial approach is both safe and effective.
Media in This Article
Figure 2
Kaplan-Meier Analysis of the Probability of Survival According to Strategy Group during 12 to 44 Months of Follow-up.Figure 3
Hazard Ratios for Death in the Two Strategy Groups with Stratification According to Five Prespecified Variables.Article Activity
- Article
More than half of all acute myocardial infarctions in the United States each year are classified as non–Q-wave myocardial infarctions, and this proportion is rising.1-3 Nevertheless, the clinical course and prognosis of this type of myocardial infarction and the best approach to management remain controversial.4-7 Since patients with non–Q-wave infarction reportedly have higher rates of both early and late ischemic complications (reinfarction and postinfarction angina), presumably because of the presence of viable but jeopardized myocardium within the perfusion zone of the infarct-related artery,5,7-16 their treatment has become increasingly aggressive.
Although the 1987 American College of Cardiology–American Heart Association guidelines for coronary arteriography17 recommended routine coronary angiography for all patients after non–Q-wave infarction, newer guidelines no longer endorse this approach to treatment.18,19 Nevertheless, early invasive management is still widely practiced. Furthermore, several recent studies of patients with acute coronary syndromes have shown either no effect or an adverse effect when routine coronary angiography is followed by early myocardial revascularization.20-23 Thus, despite the paucity of supporting data, many physicians assume that an “invasive” strategy (one characterized by routine coronary angiography followed by revascularization, if feasible) is superior to a “conservative” strategy (consisting of medical therapy, noninvasive testing, and subsequent invasive procedures if indicated by the development of spontaneous or inducible ischemia — i.e., an ischemia-guided approach) in terms of improving clinical outcomes.
To test this hypothesis, we initiated a multicenter, randomized, controlled trial to compare an invasive with a conservative strategy in patients with acute non–Q-wave myocardial infarction; the combined primary end point was death from any cause or recurrent nonfatal infarction during a minimum of 12 months of follow-up.
Methods
Study Organization
The Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial began enrollment on April 14, 1993, after the institutional review boards at 15 participating centers had approved the protocol. Two study sites were dropped within six months because of poor enrollment, and an additional two sites were added later. Thus, 15 sites completed the study. This report includes data from all 17 sites. A data-monitoring board independently reviewed the interim results at regular intervals.
Selection of Patients
Details of the trial design have been published elsewhere.24 Eligible patients had to have evolving acute myocardial infarction, a level of creatine kinase MB (CK-MB) isoenzymes that was more than 1.5 times the upper limit of normal for the hospital, and no new abnormal Q waves (or R waves) on serial electrocardiograms. Patients were excluded if they had serious coexisting conditions, ischemic complications that placed them at very high risk while in the coronary care unit (persistent or recurrent ischemia at rest despite intensive medical therapy or severe heart failure that persisted despite treatment with intravenous diuretics, vasodilators, or both). These were conditions that were deemed to pose clinical or ethical problems for the inclusion of patients in a randomized trial.24
The electrocardiographic analysis followed the Atlanta code,25 with serial tracings obtained at multiple times after the onset of infarction. At least one electrocardiogram was obtained 48 hours after admission in order to rule out the late development of Q waves.26 Electrocardiographically, the study patients had neither new, abnormal Q waves (i.e., Q waves lasting 0.04 second in two contiguous leads within a group of leads) nor R waves (more than 0.04 second in lead V1 and an R:S ratio greater than 1 in lead V2); we have previously demonstrated that these criteria reliably exclude evolving posterior infarction.26,27
Randomization Procedure
The study patients gave informed, written consent and were randomly assigned to a study group within 24 to 72 hours after the onset of symptoms according to the adaptive-allocation procedure,28 which maximized the probability of balance between the treatment groups within the medical centers and with respect to each of five variables used for stratification: age, previous myocardial infarction, use of thrombolytic therapy, anterior location of the infarct, and ST-segment depression on the electrocardiogram obtained at entry.
Testing and Treatment
Patients assigned to the early invasive strategy underwent coronary angiography as the initial diagnostic test soon after randomization. Thereafter, the management guidelines of the Thrombolysis in Myocardial Infarction trial (TIMI IIIB) for revascularization were followed.20 In patients with clinically significant single-vessel coronary artery disease, balloon angioplasty or, rarely, directional atherectomy was considered, whereas bypass surgery was recommended for patients with multivessel disease. In contrast to the TIMI IIIB guidelines, however, our protocol did not require early myocardial revascularization; investigators at each study site were allowed to decide whether to perform only revascularization of a culprit stenosis, perform complete revascularization, or continue medical therapy.
Patients assigned to the early conservative strategy underwent radionuclide ventriculography to assess left ventricular function as the initial noninvasive test; this was followed before discharge by a symptom-limited treadmill exercise test (according to the standard Bruce protocol) with planar thallium scintigraphy or thallium scintigraphy with single-photon-emission computed tomography. Patients who were unable to exercise to a level of at least 5 metabolic equivalents (MET) received intravenous dipyridamole (0.56 mg per kilogram of body weight) and then underwent perfusion scintigraphy.
Coronary angiography with or without revascularization was performed in patients randomly assigned to the conservative strategy only if one or more of the following three criteria were met: the patient had recurrent postinfarction angina with ischemic electrocardiographic changes; the patient had ST-segment depression of at least 2 mm on an electrocardiogram recorded during peak exercise; or there were redistribution defects in two or more different vascular regions on thallium scintigraphy, or one redistribution defect with increased uptake of thallium by the lung. Investigators at the study site decided whether to perform myocardial revascularization in patients who had objective evidence of ischemia.
Patients in both groups received enteric-coated aspirin (325 mg per day) and long-acting diltiazem (Cardizem, Hoechst Marion Roussel, Kansas City, Mo.; 180 to 300 mg per day), on the basis of the reported benefit of this combination for secondary prevention.5,7,29-32 In addition, patients could receive any other standard medical therapy during hospitalization, including nitroglycerin, angiotensin-converting–enzyme inhibitors, beta-blockers, dose-adjusted intravenous heparin, and if clinically indicated, thrombolytic therapy.24
Follow-up
Enrollment ended on December 31, 1995. Patients were seen one month after discharge and at three-month intervals thereafter until the trial ended on December 31, 1996.
End Points
The primary end point of the trial was death or nonfatal myocardial infarction. An independent, three-member end-points committee, whose members were unaware of the treatment assignments, reviewed and adjudicated all suspected primary end points. We also analyzed overall mortality and major procedural complications after coronary angiography or myocardial revascularization.
Statistical Analysis
Sample size was calculated for an equivalence study on the basis of binomial proportions.33 Our null hypothesis was that 20 percent of each group would reach a primary end point during 12 months of follow-up,30,34 and we postulated that the null hypothesis of equivalence would be rejected if the difference between the groups exceeded 7.5 percent, with a two-sided significance level of 0.05 and 80 percent power.24 The study chairman and executive committee were masked with respect to the results throughout the trial. Formal interim analyses for efficacy were conducted by the data-monitoring board, using accepted methods.24,35,36
Continuous data are presented as means ±SD. Odds ratios and 95 percent confidence intervals were used to compare the strategies with respect to major clinical outcomes. Survival curves were used to characterize the timing of the primary end point during follow-up, according to the method of Kaplan and Meier.37 The Cox proportional-hazards regression model38 was used to adjust for covariates in the analysis of the interaction between the strategy assignment and the five prespecified covariates. All tests of significance were two-tailed, and the strategies were compared according to the intention-to-treat principle.
Results
Characteristics of the Study Population
Among 2738 patients with non–Q-wave myocardial infarction confirmed by measurement of CK-MB isoenzymes who were identified at screening, 920 patients (34 percent) were randomly assigned to treatment groups: 462 to the invasive-strategy group and 458 to the conservative-strategy group. A total of 247 patients (9 percent) were excluded because of very-high-risk ischemic complications during the first 48 hours after the onset of infarction.24 The base-line characteristics of the subjects are shown in Table 1Table 1
Base-Line Characteristics of the Patients Randomly Assigned to the Invasive and Conservative Strategies.. Ninety-seven percent of the study population were men. Eight percent of the patients were older than 75 years, and 40 percent were older than 65. Vital status at one year was verified for 913 patients (the other 7 patients were assumed to be alive after searches of death registries had negative results); follow-up at one year was more than 99 percent complete.End-Point Analyses
A total of 152 cardiac events (80 deaths and 72 nonfatal infarctions) occurred in 138 patients in the invasive-strategy group, as did 139 cardiac events (59 deaths and 80 nonfatal infarctions) in 123 patients in the conservative-strategy group (P=0.35) during an average of 23 months of follow-up (range, 12 to 44). As shown in Figure 1Figure 1
Kaplan–Meier Analysis of the Probability of Event-free Survival According to Strategy Group during 12 to 44 Months of Follow-up., the cumulative rates of death or nonfatal infarction in the groups did not differ significantly during long-term follow-up (hazard ratio for the conservative-strategy group as compared with the invasive-strategy group, 0.87; 95 percent confidence interval, 0.68 to 1.10), although there were striking differences between the groups in early clinical outcomes (i.e., clinical outcomes in the first 12 months). The frequency of death or nonfatal myocardial infarction was higher in the invasive-strategy group than in the conservative-strategy group before hospital discharge (36 vs. 15 events, P=0.004), at one month (48 vs. 26 events, P=0.012), and at one year (111 vs. 85 events, P= 0.05). The same was true for the rate of death (21 vs. 6 deaths, P=0.007; 23 vs. 9, P=0.21; and 58 vs. 36, P=0.025, respectively).During long-term follow-up, cumulative mortality from all causes did not differ significantly between the patients assigned to the conservative strategy and those assigned to the invasive strategy (hazard ratio, 0.72; 95 percent confidence interval, 0.51 to 1.01) (Figure 2Figure 2
Kaplan-Meier Analysis of the Probability of Survival According to Strategy Group during 12 to 44 Months of Follow-up.). Even among the 805 patients who did not receive thrombolytic therapy, there were more deaths in the invasive-strategy group (69 deaths) than in the conservative-strategy group (58). There were no significant differences between the groups in the incidence of nonfatal myocardial infarction during follow-up. Finally, there was remarkable consistency among the study sites; patients in the invasive-strategy group fared worse than those in the conservative-strategy group at 11 of 15 centers (73 percent).Clinical Outcomes According to Treatment Strategy and Myocardial Revascularization
The clinical outcomes of all 920 patients are summarized in Table 2Table 2
Clinical Outcomes of Patients Who Underwent Coronary Angiography with Revascularization, Coronary Angiography without Revascularization, or No Coronary Angiography.. Among the 462 patients assigned to the invasive strategy, 442 (96 percent) underwent coronary angiography (435 before hospital discharge and 439 by 30 days after the onset of symptoms). Among the 458 patients in the conservative-strategy group, only 24 percent (110 patients) underwent coronary angiography before discharge, and 29 percent (133 patients) by 30 days. Of the 110 patients who underwent catheterization before discharge, 45 percent had recurrent angina with ischemic electrocardiographic changes, 20 percent had ST-segment deviation of at least 2 mm during exercise testing, and 47 percent had one or more reversible perfusion defects during thallium scintigraphy.The prevalence of multivessel coronary artery disease was high; 74 percent of patients in the invasive-strategy group and 80 percent of those in the conservative-strategy group had substantial left-main-stem stenosis, reduction of 50 percent or more of the luminal diameter in two or more major epicardial coronary arteries, or both.
A total of 204 patients (44 percent) underwent myocardial revascularization in the invasive-strategy group (95 had coronary-artery bypass graft surgery [CABG], 98 underwent percutaneous transluminal coronary angioplasty [PTCA], and 11 had both procedures), as did 152 (33 percent) in the conservative-strategy group (87 underwent CABG, 55 PTCA, and 10 both procedures) (Table 2 and Table 3Table 3
Mortality 30 Days after Revascularization in the Two Treatment-Strategy Groups.). Revascularization was performed earlier after randomization and within a narrower interval in the invasive-strategy group. Mortality 30 days after PTCA was 0 (0 of 98 patients) in the invasive-strategy group and 3.6 percent (2 of 55) in the conservative-strategy group — for a composite rate of 1.3 percent (Table 3). The 30-day death rate among patients who underwent only CABG was 7.7 percent (14 of 182 patients); 11 deaths occurred in the invasive-strategy group and 3 in the conservative-strategy group. Among the 21 patients who underwent both CABG and PTCA, only one death (4.8 percent) occurred (in a patient assigned to the conservative strategy). Overall, the death rate 30 days after revascularization was 4.8 percent (17 of 356 patients).Of the 236 patients assigned to the conservative strategy who did not undergo angiography (52 percent), only 1.3 percent had had a nonfatal infarction or died by 30 days, and 11 percent by 1 year. The mortality was only 1 percent at 30 days and 6 percent at 1 year. Finally, the duration of hospitalization was significantly longer in the invasive-strategy group than in the conservative-strategy group (9.5 vs. 8.2 days, P=0.024).
Therapy with Drugs and Devices
At hospital discharge (a mean of 8.8 days after the onset of symptoms), 89 percent of patients were receiving aspirin, 52 percent a beta-blocker, and 55 percent a calcium-channel antagonist (diltiazem in 42 percent and another drug in 13 percent). There were no significant differences between the groups in use of medications. Certain newer treatment methods emerged during the course of the trial and were approved for clinical use after enrollment began; among them were stenting (in mid-1994) and platelet glycoprotein IIb/IIIa receptor antagonists (in 1995). Ticlopidine was not used routinely after PTCA.
Interaction Analysis
The lengths of time to death and to a cardiac event (death or nonfatal myocardial infarction) were compared for each of the five prespecified variables used in stratification in order to determine whether the main results were consistent among subgroups (Figure 3Figure 3
Hazard Ratios for Death in the Two Strategy Groups with Stratification According to Five Prespecified Variables.). For death, there was moderately strong statistical evidence of benefit in the conservative-strategy group for 4 of 10 subgroups (patients who underwent thrombolysis, those with no prior infarction, those with no ST-segment depression, and those who were 60 or older). In no subgroup was the invasive strategy associated with a better outcome. For the combined primary end point, neither strategy conferred a statistically reliable advantage in any subgroup.Discussion
In this large, prospective, randomized trial of management of non–Q-wave myocardial infarction, we observed a substantial 28 percent rate of cardiac events during follow-up of 12 to 44 months, but no early or late clinical benefit with routine invasive management. Although the cumulative rate of death or recurrent infarction did not differ significantly between the two study groups, the rates of death or nonfatal myocardial infarction and of death were significantly higher during the first year of follow-up among patients randomly assigned to the invasive strategy. Both at hospital discharge and at 30 days, the rate of cardiac events and deaths among patients in the invasive-strategy group was increased by a factor of two to three, as compared with the rate in the conservative-strategy group. Moreover, overall mortality was significantly lower throughout the entire first year after infarction among patients assigned to the conservative strategy. The mortality curves for each strategy tended to converge by the end of follow-up (Figure 2), a pattern that is not surprising in a population of patients with non–Q-wave myocardial infarction who were followed for up to 44 months.
For clinical and ethical reasons, we excluded a subgroup of patients with very-high-risk ischemic complications for whom an early invasive approach was clinically warranted; only 9 percent of all eligible patients with non–Q-wave infarction had such complications, however. Instead, our main goal was to assess the role of routine, early invasive management in the remaining patients with non–Q-wave infarction, more than 90 percent of the total, who were clinically stable at the time of transfer from the coronary care unit.
No subgroup of patients with non–Q-wave infarction appeared to benefit from an early invasive approach to treatment. Patients with anterior infarction, ST-segment depression on the electrocardiogram at entry, a reduced ejection fraction, or a previous infarction did not fare better with routine invasive management than with conservative treatment. Exclusion of the 115 patients who received early thrombolytic therapy did not change our overall findings.
Two other studies are relevant to our findings. In TIMI IIIB, there were no significant differences in the rates of death or recurrent infarction at six weeks among 1473 patients with acute coronary syndromes or in the subgroup of 476 patients with non–Q-wave infarction who were randomly assigned to an invasive strategy (18 events) or to a conservative strategy (22 events).20 In TIMI IIIB, 64 percent of patients in the conservative-strategy group underwent coronary angiography within 6 weeks of randomization (90 percent of them within 10 days). In the current VANQWISH Trial, only 29 percent of patients in the conservative-strategy group subsequently underwent catheterization because they had objective signs of ischemia within 30 days.
The findings of the Danish Multicenter Randomized Study of Invasive versus Conservative Treatment in Patients with Inducible Ischemia after Thrombolysis in Acute Myocardial Infarction (DANAMI)39 are indirectly related to our findings in the VANQWISH Trial. In DANAMI, only patients with first infarctions treated initially with thrombolytic therapy were included; 25 percent were classified as having non–Q-wave infarctions.39 In VANQWISH, the median lengths of time from randomization to coronary angiography and revascularization in the invasive-therapy group were 2 days and 8 days, respectively, whereas in DANAMI this interval ranged from 2 to 10 weeks. The incidence of subsequent reinfarction and unstable angina was lower among patients in DANAMI who were assigned to the invasive strategy, but there was no significant difference in mortality.39 The combined rate of death or reinfarction in DANAMI during a median follow-up of 2.4 years was 12 percent, whereas in the VANQWISH Trial it was 28 percent. Thus, as compared with the patient groups in both TIMI IIIB20 and DANAMI,39 our patients were at higher risk.24 There was no clear benefit to routine early invasive management in terms of reducing mortality in any of the trials.
In the VANQWISH Trial, the 30-day death rate after CABG (7.7 percent) occurred in patients at moderately high risk among whom the event rate probably reflects the severity of their illness. Our findings are consistent with other reports that emphasize the fact that preoperative variables that identify patients as being at high risk (such as recent infarction) are associated with higher short-term mortality after CABG.40-43 A recent study of 5517 patients who underwent CABG in 1993 showed that in-hospital mortality was highest among patients who underwent surgery within seven days of myocardial infarction (13 percent); who had previously undergone CABG (11 percent); who had peripheral or cerebral vascular disease (9 percent); who were 65 years of age or older (4 percent); or who had diabetes (3 percent).40 These characteristics were common among our patients with non–Q-wave infarction.24
Several implications of our findings are noteworthy. First, the very low 30-day death rate after PTCA (1.3 percent) — even without stenting — was virtually identical to that observed at 30 days with conservative ischemia-guided management and no coronary angiography (1 percent) (Table 2). Second, early conservative management did not imply only watchful waiting; it embodied medical therapy, careful noninvasive testing, and coronary angiography, with or without myocardial revascularization, as indicated when ischemia recurred. Third, we found no evidence that using a routine strategy of early invasive treatment resulted in more expeditious management or shorter hospitalizations. Finally, routine coronary angiography in otherwise stable patients often leads to unnecessary revascularization procedures such as PTCA, the rate of which rose almost 6000 percent between 1980 and 1992.44
Our study has limitations. First, the study was not designed to compare myocardial revascularization with intensive medical therapy in survivors of acute non–Q-wave myocardial infarction. Considering the low rate of cardiac events among patients treated with conservative management, it seems unlikely that more aggressive intervention would have resulted in a different outcome. Nevertheless, clinical outcomes in the invasive-strategy group could have been different if a larger percentage of patients had undergone revascularization. Second, the very low percentage of female patients enrolled limits the generalizability of the overall findings to women. Third, the VANQWISH Trial was conducted before coronary stents or platelet glycoprotein IIb/IIIa receptor antagonists were widely available. Although it is possible that clinical outcomes might have been different in the invasive-strategy group if we had used stents, novel antiplatelet agents, or both, the long-term effects of such therapies in this population remain uncertain.
In summary, in this predominantly male population of moderate-to-high-risk patients with non–Q-wave myocardial infarction, we found no evidence that clinical outcomes were improved by a routine strategy of early invasive treatment; in fact, we observed substantial risk overall with this approach during the first year after infarction. By contrast, patients who were treated initially according to a conservative strategy had significantly lower mortality at hospital discharge, at one month, and at one year. These findings indicate that most patients with non–Q-wave myocardial infarction are not likely to benefit from routine early invasive treatment. A conservative initial strategy based on an ischemia-guided approach to management after infarction is both safe and effective.
Supported by a research grant from the Department of Veterans Affairs Cooperative Studies Program and by an unrestricted research grant from Hoechst Marion Roussel.
Source Information
From the Veterans Affairs Medical Center and the State University of New York Health Science Center, Syracuse (W.E.B.); the Veterans Affairs Medical Center, San Antonio, Tex. (R.A.O.); the Veterans Affairs Medical Center, Albuquerque, N.M. (M.H.C.); the Veterans Affairs Medical Center, Houston (A.S.B.); the Veterans Affairs Medical Center, Fresno, Calif. (P.C.D.); the James A. Haley Veterans Affairs Medical Center, Tampa, Fla. (R.G.Z); the Veterans Affairs Medical Center, Cincinnati (L.F. W.); Jewish Hospital, Washington University School of Medicine, St. Louis (R.E.K.); the Veterans Affairs Medical Center, Gainesville, Fla. (C.J.P.); the Jerry L. Pettis Veterans Affairs Medical Center, Loma Linda, Calif. (D.R.F.); and the Department of Veterans Affairs Cooperative Studies Program Coordinating Center, Palo Alto, Calif. (B.K.C., P. W.L.).
Address reprint requests to Dr. Boden at the Medical Service, Veterans Affairs Healthcare Network of Upstate New York, 800 Irving Ave., Syracuse, NY 13210.
The study sites, investigators, and study personnel participating in the VANQWISH Trial are listed in the Appendix.
Appendix
The following persons and institutions participated in the VANQWISH Trial: Study Chairman's Office (Syracuse, N.Y.): W. Boden (chairman), H. Dai and D. Joyce (project coordinators), and P. Crawford (program assistant); Veterans Affairs Medical Centers: Albuquerque — M. Crawford, M. Holland, K. Wagoner; Cincinnati — L. Wexler, V. Thomas; Fresno, Calif. — P. Deedwania, E. Carbajal, R. Kanefield; Gainesville, Fla. — C. Pepine, J. Green, Jr., M. Limacher, E. Handberg-Thurmond, N. Davis; Hines, Ill. — M. Hwang, S. Lemoine; Houston — A. Blaustein, C. Rowe; Lexington, Ky. — C. Chasen, P. Frazier; Little Rock, Ark. — M. Murphy, J. Doherty, E. Smith, III, J. Calkins, Jr., A. Bierle; Loma Linda, Calif. — D. Ferry, A. Jacobson, G. Frivold, K. Okubo; Nashville — R. Smith, S. Levine, R. Bruce; Palo Alto, Calif. — J. Giacomini, C. Stepp; Richmond, Va. — R. Jesse, A. Minisi, C. Murphy; San Antonio, Tex. — R. O'Rourke, A. Jain, C. Patterson; San Diego, Calif. — A. Maisel; Seattle — K. Lehmann, J. Caldwell, S. Ferris; St. Louis — H. Stratmann, L. Younis, L. Conwill; Tampa, Fla. — R. Zoble, G. Cintron, J. Sullebarger, J. Umberger; Cooperative Studies Program Coordinating Center (Palo Alto, Calif.): P. Lavori (chief); D. Bloch, B. Chow, M. Iwane, R. Thomas, A. Busette, L. Sheridan, R. Yezzi, S. Jones, J. King, K. Small; Cooperative Studies Program Clinical Research Pharmacy Coordinating Center (Albuquerque, N.M.): C. Haakenson, M. Miller, L. Guidarelli, L. Vasquez, F. Chacon, C. Tripp, G. Garcia, J. Price; Cooperative Studies Program Central Office: P. Huang, Washington, D.C., and J. Gold, Boston; Planning Committee: J. Abrams, University of New Mexico, Albuquerque; T. Bigger, Columbia University, New York; P. Carson, Georgetown University, Washington, D.C.; R. Kleiger, Jewish Hospital of St. Louis, St. Louis; J. Leppo, University of Massachusetts, Worcester; M. Moskowitz, Boston University, Boston; M. Smith, Veterans Affairs Medical Center, Manchester, N.H.; M. Hlatky, Stanford University, Stanford, Calif.; R. Thomas, Veterans Affairs Medical Center, Palo Alto, Calif.; End-Points Committee: C. Cannon (chairman), Brigham and Women's Hospital, Boston; K. Eagle, University of Michigan Medical Center, Ann Arbor; D. Losordo, St. Elizabeth's Hospital, Boston; Data Monitoring Board: B. Pitt (chairman), University of Michigan Medical Center, Ann Arbor; M. Moskowitz, University Hospital, Boston; A. Moss, University of Rochester Medical Center, Rochester, N.Y.; R. DeBusk, Stanford University School of Medicine, Palo Alto, Calif.; S. Azen, University of Southern California, Los Angeles; R. Schlant, Emory University School of Medicine, Atlanta; J. Wittes, Statistics Collaborative, Washington, D.C.; Core Laboratories: R. Kleiger, Electrocardiography Core Laboratory, Jewish Hospital–Washington University School of Medicine, St. Louis; J. Leppo, Nuclear Cardiology Quality Assessment Laboratory, University of Massachusetts Medical Center, Worcester; R. Kerensky, Coronary Angiography Quality Assessment Laboratory, University of Florida, Gainesville.
- References
References
1
Boden WE. Investigation and treatment of the patient with non-Q-wave myocardial infarction. In: Roberts R, ed. Coronary heart disease and risk factors. Vol. 3 of Clinical cardiovascular therapeutics. Mount Kisco, N.Y.: Futura Publishing, 1991:113-65.
2
Boden WE ,Roberts R . Prognosis and management of patients with non-Q-wave myocardial infarction. Prog Cardiol 1991;4:143-1603
Goldberg RJ ,Gore JM ,Alpert JS ,Dalen JE . Non-Q wave myocardial infarction: recent changes in occurrence and prognosis -- a community-wide perspective. Am Heart J 1987;113:273-279[Erratum, Heart J 1987;114:1535.]
CrossRef | Web of Science | Medline4
Gibson RS . Non-Q-wave myocardial infarction: diagnosis, prognosis, and management. Curr Probl Cardiol 1988;13:9-72
Medline5
Gibson RS. Non-Q-wave myocardial infarction. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 2. Philadelphia: Lippincott-Raven, 1996:1097-123.
6
Klein LW ,Helfant RH . The Q-wave and non-Q-wave myocardial infarction: differences and similarities. Prog Cardiovasc Dis 1986;29:205-220
CrossRef | Web of Science | Medline7
Liebson PR ,Klein LW . The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997;39:399-444
CrossRef | Web of Science | Medline8
Marmor A ,Sobel BE ,Roberts R . Factors presaging early recurrent myocardial infarction (“extension“). Am J Cardiol 1981;48:603-610
CrossRef | Web of Science | Medline9
Nicod P ,Gilpin E ,Dittrich H , et al. Short- and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population. Circulation 1989;79:528-536
CrossRef | Web of Science | Medline10
Chung MK ,Bosner MS ,McKenzie JP ,Shen J ,Rich MW . Prognosis of patients ≥70 years of age with non-Q-wave acute myocardial infarction compared with younger patients with similar infarcts and with patients ≥70 years of age with Q-wave acute myocardial infarction. Am J Cardiol 1995;75:18-22
CrossRef | Web of Science | Medline11
Rich MW ,Bosner MS ,Chung MK ,Shen J ,McKenzie JP . Is age an independent predictor of early and late mortality in patients with acute myocardial infarction? Am J Med 1992;92:7-13
CrossRef | Web of Science | Medline12
Maisel AS ,Ahnve S ,Gilpin E , et al. Prognosis after extension of myocardial infarct: the role of Q wave or non-Q wave infarction. Circulation 1985;71:211-217
CrossRef | Web of Science | Medline13
Bosch X ,Theroux P ,Waters DD ,Pelletier GB ,Roy D . Early postinfarction ischemia: clinical, angiographic, and prognostic significance. Circulation 1987;75:988-995
CrossRef | Web of Science | Medline14
Schechtman KB ,Capone RJ ,Kleiger RE , et al. Differential risk patterns associated with 3 month as compared with 3 to 12 month mortality and reinfarction after non-Q wave myocardial infarction: the Diltiazem Reinfarction Study Group. J Am Coll Cardiol 1990;15:940-947
CrossRef | Web of Science | Medline15
Cannon CP ,Thompson B ,McCabe CH , et al. Predictors of non-Q-wave acute myocardial infarction in patients with acute ischemic syndromes: an analysis from the Thrombolysis in Myocardial Ischemia (TIMI) III trials. Am J Cardiol 1995;75:977-981
CrossRef | Web of Science | Medline16
Huey BL ,Gheorghiade M ,Crampton RS , et al. Acute non-Q wave myocardial infarction associated with early ST segment elevation: evidence for spontaneous coronary reperfusion and implications for thrombolytic trials. J Am Coll Cardiol 1987;9:18-25
CrossRef | Web of Science | Medline17
Guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Angiography)
CrossRef | Web of Science | Medline18
Pepine CJ ,Allen HD ,Bashore TM , et al. American College of Cardiology/American Heart Association guidelines for cardiac catheterization and cardiac catheterization laboratories. J Am Coll Cardiol 1991;18:1149-1182
CrossRef | Web of Science | Medline19
Ryan TJ ,Anderson JL ,Antman EM , et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1428
CrossRef | Web of Science | Medline20
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB Trial: Thrombolysis in Myocardial IschemiaCirculation 1994;89:1545-1556
Web of Science | Medline21
Topol EJ ,Califf RM ,George BS , et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-588
Full Text | Web of Science | Medline22
The TIMI Research Group
CrossRef | Web of Science23
Rouleau JL ,Moye LA ,Pfeffer MA , et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med 1993;328:779-784
Full Text | Web of Science | Medline24
Ferry DR ,O'Rourke RA ,Blaustein AS , et al. Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. J Am Coll Cardiol 1998;31:312-320
CrossRef | Web of Science | Medline25
Boden WE ,Kleiger RE ,Gibson R , et al. Electrocardiographic and enzymatic findings in acute non-Q wave myocardial infarction. Am J Noninvasive Cardiol 1988;2:125-13326
Kleiger RE ,Boden WE ,Schechtman KB , et al. Frequency and significance of late evolution of Q-waves in patients with non-Q-wave acute myocardial infarction. Am J Cardiol 1990;65:23-27
CrossRef | Web of Science | Medline27
Boden WE ,Kleiger RE ,Gibson RS , et al. Electrocardiographic evolution of posterior acute myocardial infarction: importance of early precordial ST-segment depression. Am J Cardiol 1987;59:782-787
CrossRef | Web of Science | Medline28
Pocock SJ ,Simon R . Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115
CrossRef | Web of Science | Medline29
Gibson RS ,Boden WE ,Theroux P , et al. Diltiazem and reinfarction in patients with non-Q-wave acute myocardial infarction: results of a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-429
Full Text | Web of Science | Medline30
The Multicenter Diltiazem Postinfarction Trial Research Group
Full Text | Web of Science | Medline31
Boden WE ,Krone RJ ,Kleiger RE , et al. Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction: the Multicenter Diltiazem Post-Infarction Trial Research Group. Am J Cardiol 1991;67:335-342
CrossRef | Web of Science | Medline32
Boden WE . Management of non-Q-wave myocardial infarction: role of diltiazem versus beta-blocker therapy. J Cardiovasc Pharmacol 1990;16:Suppl 6:S55-S60
Web of Science | Medline33
Makuch R ,Simon R . Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-1040
Medline34
The Multicenter Postinfarction Research Group
Full Text | Web of Science | Medline35
Lan KKG ,DeMets DL . Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-663
CrossRef | Web of Science36
O'Brien PC ,Fleming TR . A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556
CrossRef | Web of Science | Medline37
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science38
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-22039
Madsen JK ,Grande P ,Saunamaki K , et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). Circulation 1997;96:748-755
Web of Science | Medline40
Tu JV ,Sykora K ,Naylor CD . Assessing the outcomes of coronary artery bypass graft surgery: how many risk factors are enough? J Am Coll Cardiol 1997;30:1317-1323
CrossRef | Web of Science | Medline41
Jones RH ,Hannan EL ,Hammermeister KE , et al. Identification of preoperative variables needed for risk adjustment of short-term mortality after coronary artery bypass graft surgery: Working Group Panel on the Cooperative CABG Database Project. J Am Coll Cardiol 1996;28:1478-1487
CrossRef | Web of Science | Medline42
Edwards FH ,Clark RE ,Schwartz M . Coronary artery bypass grafting: the Society of Thoracic Surgeons National Database experience. Ann Thorac Surg 1994;57:12-19
CrossRef | Web of Science | Medline43
Magovern JA ,Sakert T ,Magovern GJ , et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. J Am Coll Cardiol 1996;28:1147-1153
CrossRef | Web of Science | Medline44
Krumholz HM . Cardiac procedures, outcomes, and accountability. N Engl J Med 1997;336:1522-1523
Full Text | Web of Science | Medline
- Citing Articles (228)
Citing Articles
1
Pravin Pratap, Sameer Gupta, Michael Berlowtiz. (2011) Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach. Journal of Cardiovascular Translational Research
CrossRef2
Peter R. Sinnaeve. (2011) Routine Invasive Versus Conservative Management in Non-ST-elevation Acute Coronary Syndromes. Journal of Cardiovascular Translational Research
CrossRef3
Yuri B. Pride, C. Michael Gibson. (2011) Percutaneous Coronary Interventions in Facilities Without Cardiac Surgery on Site. Current Cardiology Reports 13:5, 432-438
CrossRef4
MENG JIANG, BEN HE, QI ZHANG. (2011) Timing of Early Invasive Intervention in Patients with Moderate to High Risk Acute Coronary Syndromes. Journal of Interventional Cardiologyno-no
CrossRef5
Mark Helfand, Sean Tunis, Evelyn P. Whitlock, Stephen G. Pauker, Anirban Basu, Jon Chilingerian, Frank E. Harrell Jr., David O. Meltzer, Victor M. Montori, Donald S. Shepard, David M. Kent, . (2011) A CTSA Agenda to Advance Methods for Comparative Effectiveness Research. Clinical and Translational Science 4:3, 188-198
CrossRef6
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef7
Christian W. Hamm, Albrecht Elsaesser. 2011. Indications in Acute Coronary Syndromes without ST Elevation (NSTE-ACS). , 232-241.
CrossRef8
E. P. Navarese, S. De Servi, C. Michael Gibson, A. Buffon, F. Castriota, J. Kubica, A. S. Petronio, F. Andreotti, G. De Luca. (2011) Early vs. delayed invasive strategy in patients with acute coronary syndromes without ST-segment elevation: a meta-analysis of randomized studies. QJM 104:3, 193-200
CrossRef9
Robert C. Hendel, Brian G. Abbott, Timothy M. Bateman, Ron Blankstein, Dennis A. Calnon, Jeffrey A. Leppo, Jamshid Maddahi, Matthew M. Schumaecker, Leslee J. Shaw, R. Parker Ward, David G. Wolinsky. (2011) The role of radionuclide myocardial perfusion imaging for asymptomatic individuals. Journal of Nuclear Cardiology 18:1, 3-15
CrossRef10
D. G. Katritsis, G. C. M. Siontis, A. Kastrati, A. W. J. van't Hof, F.-J. Neumann, K. C. M. Siontis, J. P. A. Ioannidis. (2011) Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. European Heart Journal 32:1, 32-40
CrossRef11
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef12
Kouraki Kleopatra, Kerstin Muth, Ralf Zahn, Timm Bauer, Oliver Koeth, Claus Jünger, Anselm Gitt, Jochen Senges, Uwe Zeymer. (2010) Effect of an invasive strategy on in-hospital outcome and one-year mortality in women with non-ST-elevation myocardial infarction. International Journal of Cardiology
CrossRef13
Rajendra H. Mehta, Anita Y. Chen, E. Magnus Ohman, W. Brian Gibler, Eric D. Peterson, Matthew T. Roe. (2010) Influence of transfer-in rates on quality of care and outcomes at receiving hospitals in patients with non–ST-segment elevation myocardial infarction. American Heart Journal 160:3, 405-411
CrossRef14
Patricia Palau, Julio Núñez, Juan Sanchis, Vicent Bodí, Eva Rumiz, Eduardo Núñez, Gema Miñana, Pilar Merlos, Cristina Gómez, Lorenzo Fácila, Francisco J. Chorro, Àngel Fácila. (2010) Impacto pronóstico de una estrategia invasiva en el síndrome coronario agudo sin elevación del segmento ST según la presencia o no de disfunción sistólica. Revista Española de Cardiología 63:8, 915-924
CrossRef15
Keith A.A. Fox, Tim C. Clayton, Peter Damman, Stuart J. Pocock, Robbert J. de Winter, Jan G.P. Tijssen, Bo Lagerqvist, Lars Wallentin. (2010) Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 55:22, 2435-2445
CrossRef16
Burton E. Sobel. (2010) Coronary revascularization in patients with type 2 diabetes and results of the BARI 2D trial. Coronary Artery Disease 21:3, 189-198
CrossRef17
Burton E. Sobel. (2010) A perspective on the development of coronary revascularization. Coronary Artery Disease 21:3, 199-203
CrossRef18
Michel R Hoenig, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2010. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. .
CrossRef19
Marc W. Deyell, William A. Ghali, David B. Ross, Jianguo Zhang, Brenda R. Hemmelgarn. (2010) Timing of nonemergent coronary artery bypass grafting and mortality after non-ST elevation acute coronary syndrome. American Heart Journal 159:3, 490-496
CrossRef20
BENNY MULYANTO SETIADI, LEI HAN, CHANG JING. (2010) Adverse Events Even after Percutaneous Coronary Intervention: Is There Any Way to Predict It?. Journal of Interventional Cardiology 23:1, 86-94
CrossRef21
Pawan D Patel, Rohit R Arora. (2010) Practical Implications of ACC/AHA 2007 Guidelines for the Management of Unstable Angina/Non-ST Elevation Myocardial Infarction. American Journal of Therapeutics 17:1, e24-e40
CrossRef22
Hae Chang Jeong, Youngkeun Ahn, Myung Ho Jeong, Shung Chull Chae, Seung Ho Hur, Taek Jong Hong, Young Jo Kim, In Whan Seong, Jei Keon Chae, Jay Young Rhew, In Ho Chae, Myeong Chan Cho, Jang Ho Bae, Seung Woon Rha, Chong Jin Kim, Donghoon Choi, Yang Soo Jang, Junghan Yoon, Wook Sung Chung, Jeong Gwan Cho, Ki Bae Seung, Seung Jung Park, . (2010) Long-Term Clinical Outcomes according to Initial Management and Thrombolysis In Myocardial Infarction Risk Score in Patients with Acute Non-ST-Segment Elevation Myocardial Infarction. Yonsei Medical Journal 51:1, 58
CrossRef23
Irene Lang, Sandra Forman, Aldo Maggioni, Witold Ruzyllo, Jean Renkin, Carlos Vozzi, P. Gabriel Steg, Jose-Maria Hernandez-Garcia, Krzysztof Zmudka, Manuel Jimenez-Navarro, George Sopko, Gervasio Lamas, Judith Hochman. (2009) Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). EuroIntervention 5:5, 610-618
CrossRef24
Julio Núñez, Juan Sanchis, Vicent Bodí. (2009) Estrategia de revascularización invasiva en el síndrome coronario sin elevación del segmento ST. El debate continúa. Medicina Clínica 133:18, 717-723
CrossRef25
Amit Kumar, Christopher P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part II. Mayo Clinic Proceedings 84:11, 1021-1036
CrossRef26
S. Michael Gharacholou, Karen P. Alexander. (2009) Evolving role of revascularization in older adults with acute coronary syndrome. Current Cardiovascular Risk Reports 3:5, 355-365
CrossRef27
Mehta, Shamir R., Granger, Christopher B., Boden, William E., Steg, Philippe Gabriel, Bassand, Jean-Pierre, Faxon, David P., Afzal, Rizwan, Chrolavicius, Susan, Jolly, Sanjit S., Widimsky, Petr, Avezum, Alvaro, Rupprecht, Hans-Jurgen, Zhu, Jun, Col, Jacques, Natarajan, Madhu K., Horsman, Craig, Fox, Keith A.A., Yusuf, Salim, . (2009) Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine 360:21, 2165-2175
Full Text28
Ralf Zahn, Uwe Zeymer. (2009) Akuter Myokardinfarkt: Akut-PCI in jedem Krankenhaus versus Akut-PCI im spezialisierten Zentrum. Herz Kardiovaskuläre Erkrankungen 34:3, 211-217
CrossRef29
Stefano Savonitto, Nuccia Morici, Alice Sacco, Silvio Klugmann. (2009) Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients. Future Cardiology 5:1, 27-41
CrossRef30
L.M. Dijksman, A. Hirsch, F. Windhausen, F.F. Asselman, J.G.P. Tijssen, M.G.W. Dijkgraaf, R.J. de Winter. (2009) Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. International Journal of Cardiology 131:2, 204-211
CrossRef31
Pierluigi Tricoci. (2008) Time to coronary angiography in patients with non-ST-segment elevation acute coronary syndrome: how fast should patients go to the catheterization laboratory?. Current Opinion in Cardiology 23:6, 585-590
CrossRef32
J.-P. Monassier, L. Jacquemin, O. Roth, R. LeBouar, D. Kénizou, A. Calatan, J.-Y. Wiedemann, M. Moussaoui, L. Diene, J. Lévy. (2008) Coronarographie normale au cours des syndromes coronariens aigus non ST + : une fausse bonne nouvelle ?. Annales de Cardiologie et d'Angéiologie 57:5, 275-283
CrossRef33
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2008. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef34
R. Zahn, U. Zeymer. (2008) Interventionelle Therapie des akuten Herzinfarkts. Der Internist 49:9, 1038-1046
CrossRef35
K. Alexiou, U. Kappert, A. Staroske, D. Joskowiak, M. Wilbring, K. Matschke, S. M. Tugtekin. (2008) Coronary surgery for acute coronary syndrome: which determinants of outcome remain?. Clinical Research in Cardiology 97:9, 601-608
CrossRef36
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef37
Konstantin Alexiou, M. Wilbring, U. Kappert, A. Staroske, D. Joskowiak, K. Matschke, S. M. Tugtekin. (2008) Koronarchirurgie im akuten Koronarsyndrom. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 22:4, 197-203
CrossRef38
Evangelos Giannitsis, Hannsjörg Baum, Thomas Bertsch, Martin Juchum, Margit Müller-Bardorff, Bo Jørgensen, Agathe Böhmer, Martina Rebmann, Jürgen Schäffler, Michael Schwab, Rainer Zerback. (2008) Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood. Clinical Chemistry and Laboratory Medicine 46:5, 630-638
CrossRef39
Raisuke Iijima, Gjin Ndrepepa, Julinda Mehilli, Franz-Josef Neumann, Stefanie Schulz, Jurriën Berg, Olga Bruskina, Franz Dotzer, Josef Dirschinger, Peter B. Berger, Albert Schömig, Adnan Kastrati. (2008) Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology 97:3, 160-168
CrossRef40
William E. Boden, Prediman K. Shah, Vipul Gupta, E. Magnus Ohman. (2008) Contemporary Approach to the Diagnosis and Management of Non–ST-Segment Elevation Acute Coronary Syndromes. Progress in Cardiovascular Diseases 50:5, 311-351
CrossRef41
Philip W. Lavori, Ree Dawson. (2008) Adaptive Treatment Strategies in Chronic Disease. Annual Review of Medicine 59:1, 443-453
CrossRef42
Sung Gyu An, Tae Ik Park, Sang Hyun Lee, Hyung Ha Jang, Dong Won Lee, Jae Kyung Ha, Han Cheol Lee, Jun Kim, June Hong Kim, Kook Jin Chun, Taek Jong Hong, Yung Woo Shin. (2008) Prognosis According to the Timing of Percutaneous Coronary Intervention in an Acute Non-ST Segment Elevation Myocardial Infarction. Korean Circulation Journal 38:1, 23
CrossRef43
Louise Pilote, Christine A. Beck, Mark J. Eisenberg, Karin Humphries, Lawrence Joseph, John R. Penrod, Jack V. Tu. (2008) Comparing invasive and noninvasive management strategies for acute myocardial infarction using administrative databases. American Heart Journal 155:1, 42-48
CrossRef44
Alan B. Storrow, Fred S. Apple, Alan H.B. Wu, Robert L. Jesse, Gary S. Francis, Robert H. Christenson, Christopher P. Cannon, David A. Morrow, L. Kristin Newby, Jan Ravkilde, Wilson Tang. (2007) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Point of Care: The Journal of Near-Patient Testing & Technology 6:4, 215-222
CrossRef45
Igal Teplitsky, Abid Assali, Eli Lev, David Brosh, Hana Vaknin-Assa, Ran Kornowski. (2007) Results of percutaneous coronary interventions in patients ≥90 years of age. Catheterization and Cardiovascular Interventions 70:7, 937-943
CrossRef46
Elin Trägårdh, Mikaela Claesson, Galen S. Wagner, Sophia Zhou, Olle Pahlm. (2007) Detection of acute myocardial infarction using the 12-lead ECG plus inverted leads versus the 16-lead ECG (with additional posterior and right-sided chest electrodes). Clinical Physiology and Functional Imaging 27:6, 368-374
CrossRef47
Giuseppe Tarantini, Renato Razzolini, Angelo Ramondo, Massimo Napodano, Anna Manica, Enrico Favaretto, Sabino Iliceto. (2007) Patient risk profile and benefit from an invasive approach in the initial management of non-ST-segment elevation acute coronary syndrome. Journal of Cardiovascular Medicine 8:10, 799-802
CrossRef48
(2007) Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Revista Española de Cardiología 60:10, 1070.e1-1070.e80
CrossRef49
Ramya Raghavan, Bruno S. Benzaquen, Lawrence Rudski. (2007) Timing of bypass surgery in stable patients after acute myocardial infarction. Canadian Journal of Cardiology 23:12, 976-982
CrossRef50
Rohit Bhatheja, Debabrata Mukherjee. (2007) Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. Critical Care Clinics 23:4, 709-735
CrossRef51
Julio Núñez, Juan Sanchis, Eduardo Núñez, Vicent Bodi, Vicente Bertomeu-González, Maria J. Bosch, Enrique Santas, Lorenzo Fácila, Francisco J. Chorro, Cristina Gómez, Luciano Consuegra, Angel Llàcer. (2007) Prognostic differences between routine invasive and conservative strategies for the management of high-risk, non-ST segment acute coronary syndromes: Experience from two consecutive periods in a single center. European Journal of Internal Medicine 18:5, 409-416
CrossRef52
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef53
Scott A. McKee, Robert J. Applegate, John R. Hoyle, Matthew T. Sacrinty, Michael A. Kutcher, David C. Sane. (2007) Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. American Heart Journal 154:1, 159-164
CrossRef54
Stephen E. Van Horn, Calin V. Maniu. (2007) Management of non–ST-Segment Elevation Myocardial Infarction. Medical Clinics of North America 91:4, 683-700
CrossRef55
Hae-Chang Jeong, Myung Ho Jeong, Young Keun Ahn, Sung Chull Chae, Young Jo Kim, Seung Ho Hur, Dong Hoon Choi, Jung Han Yoon, Jei Keon Chae, Doo Il Kim, Bon Kwon Koo, Jin Yong Hwang, Seok Kyu Oh, Kee Sik Kim, Kyung Tae Jeong, Chong Jin Kim, Wook Sung Chung, Yang Soo Jang, . (2007) In-Hospital Outcome According to the Initial Management and the "Thrombolysis in Myocardial Infarction Risk Score" of Acute Non-ST Segment Elevation Myocardial Infarction. Korean Circulation Journal 37:11, 550
CrossRef56
(2007) Invited Synopses. Acute Cardiac Care 9:3, 134-174
CrossRef57
John J. Mahmarian, Leslee J. Shaw, Neil G. Filipchuk, Habib A. Dakik, Sherif S. Iskander, Terrence D. Ruddy, Milena J. Henzlova, Felix Keng, Adel Allam, Lemuel A. Moyé, Craig M. Pratt. (2006) A Multinational Study to Establish the Value of Early Adenosine Technetium-99m Sestamibi Myocardial Perfusion Imaging in Identifying a Low-Risk Group for Early Hospital Discharge After Acute Myocardial Infarction. Journal of the American College of Cardiology 48:12, 2448-2457
CrossRef58
Abelardo Martinez-Rumayor, James L. Januzzi. (2006) Non-ST Segment Elevation Acute Coronary Syndromes: A Comprehensive Review. Southern Medical Journal 99:10, 1103-1110
CrossRef59
Anthony A. Bavry, Dharam J. Kumbhani, Andrew N. Rassi, Deepak L. Bhatt, Arman T. Askari. (2006) Benefit of Early Invasive Therapy in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:7, 1319-1325
CrossRef60
Stefan K. James, Johan Lindbäck, Johanna Tilly, Agneta Siegbahn, Per Venge, Paul Armstrong, Robert Califf, Maarten L. Simoons, Lars Wallentin, Bertil Lindahl. (2006) Troponin-T and N-Terminal Pro-B-Type Natriuretic Peptide Predict Mortality Benefit From Coronary Revascularization in Acute Coronary Syndromes. Journal of the American College of Cardiology 48:6, 1146-1154
CrossRef61
Richard G Bach. (2006) The early invasive strategy revisited: FRISC II at 5 years. The Lancet 368:9540, 966-969
CrossRef62
José Félix Meco López, Emili Corbella Ingles, Carmen Sanclemente Anso, Marta Miralles Fortuny, Iziar Sarasa Corral, Ramon Pujol Farriols, Xavier Pintó Sala. (2006) Efectividad de un programa de prevención secundaria de la arteriosclerosis en el control de las dislipemias en pacientes con enfermedad arterial coronaria. Clínica e Investigación en Arteriosclerosis 18:4, 128-136
CrossRef63
Michel R Hoenig, Jenny Doust, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2006. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. .
CrossRef64
Sripal Bangalore, Siu-Sun Yao, Jyothy Puthumana, Farooq A. Chaudhry. (2006) Incremental Prognostic Value of Stress Echocardiography Over Clinical and Stress Electrocardiographic Variables in Patients With Prior Myocardial Infarction: "Warranty Time" of a Normal Stress Echocardiogram. Echocardiography 23:6, 455-464
CrossRef65
David H. Fitchett, Bjug Borgundvaag, Warren Cantor, Eric Cohen, Sanjay Dhingra, Stephen Fremes, Milan Gupta, Michael Heffernan, Heather Kertland, Mansoor Husain, Anatoly Langer, Eric Letovsky, Shaun G. Goodman. (2006) Non-ST segment elevation acute coronary syndromes: A simplified risk-oriented algorithm. Canadian Journal of Cardiology 22:8, 663-677
CrossRef66
Robert H. Christenson. (2006) Insights Into Development of the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Point-of-Care Testing for Biomarkers of Cardiac Injury. Point of Care: The Journal of Near-Patient Testing & Technology 5:1, 13-19
CrossRef67
Arno Breeman, Jan Paul Ottervanger, Eric Boersma, Giuseppe De Luca. (2006) Coronary revascularization for non-ST elevation acute coronary syndrome: state of the art. Journal of Cardiovascular Medicine 7:2, 108-113
CrossRef68
Benjamin M. Scirica, David A. Morrow. (2006) Appropriate invasive and conservative treatment approaches for patients with non-ST-elevation MI. Current Treatment Options in Cardiovascular Medicine 8:1, 13-21
CrossRef69
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, e1-e121
CrossRef70
Jeffrey Tabas, Erin McNutt. (2005) Treatment of Patients with Unstable Angina and Non-ST Elevation Myocardial Infarction. Emergency Medicine Clinics of North America 23:4, 1027-1042
CrossRef71
Jaume Candell-Riera, Julián Rodríguez, Adriana Puente, Osvaldo Pereztol-Valdés, Joan Castell-Conesa, Santiago Aguadé-Bruix. (2005) SPECT de perfusión miocárdica en los pacientes diagnosticados de infarto de miocardio sin onda Q. Medicina Clínica 125:15, 574-577
CrossRef72
de Winter, Robbert J., Windhausen, Fons, Cornel, Jan Hein, Dunselman, Peter H.J.M., Janus, Charles L., Bendermacher, Peter E.F., Michels, H. Rolf, Sanders, Gerard T., Tijssen, Jan G.P., Verheugt, Freek W.A., . (2005) Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. New England Journal of Medicine 353:11, 1095-1104
Full Text73
Philip W. Lavori. (2005) Improving Treatment of Depression in the Elderly. Journal of Clinical Psychopharmacology 25:Supplement 1, S38-S44
CrossRef74
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2005. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef75
(2005) Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Revista Española de Cardiología 58:6, 679-728
CrossRef76
Brendan Duffy, Deepak L Bhatt. (2005) Antiplatelet Agents in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 5:5, 307-318
CrossRef77
Sven Plein, John P. Greenwood, John P. Ridgway, Gillian Cranny, Stephen G. Ball, Mohan U. Sivananthan. (2004) Assessment of non–ST-segment elevation acute coronary syndromes with cardiac magnetic resonance imaging. Journal of the American College of Cardiology 44:11, 2173-2181
CrossRef78
C. Pirich, S. Graf, M. Behesthi. (2004) Diagnostic and Prognostic Impact of Nuclear Cardiology in the Management of Acute Coronary Syndromes and Acute Myocardial Infarction. Imaging Decisions MRI 8:3, 9-16
CrossRef79
Alan H.B Wu, Andrew Smith, Robert H Christenson, MaryAnn M Murakami, Fred S Apple. (2004) Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clinica Chimica Acta 346:2, 211-219
CrossRef80
Andrew E. Arai, Glenn A. Hirsch. (2004) Q-Wave and Non-Q-Wave Myocardial Infarctions Through the Eyes of Cardiac Magnetic Resonance Imaging**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 44:3, 561-563
CrossRef81
Jorge F. Saucedo, Thomas A. Hennebry. (2004) Use of the early invasive approach in the management of acute coronary syndromes. Current Cardiology Reports 6:4, 287-291
CrossRef82
Howard C. Herrmann, Sabina A. Murphy, Peter M. Dibattiste, Paul T. Delucca, Laura A. Demopoulos, C Michael Gibson, Christopher P. Cannon. (2004) Greater Benefit of Early Invasive Strategy for Unstable Angina and Non-ST Elevation Myocardial Infarction in United States Compared With Non-United States Patients. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 3:2, 95-100
CrossRef83
Marco Zimarino, Raffaele De Caterina. (2004) Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: From Pharmacology to Individual Patient???s Therapy. Journal of Cardiovascular Pharmacology 43:4, 477-484
CrossRef84
T. Niemann, R. Labouriau, H. Toft Sorensen, N. Thorsgaard, T. Toftegaard Nielsen. (2004) Prognostic impact of different regional referral practices for interventional investigation and coronary treatment after exercise testing: a population-based 5-year follow-up study. Journal of Internal Medicine 255:4, 478-485
CrossRef85
William H. Wehrmacher. (2004) Unstable angina. Comprehensive Therapy 30:1, 6-9
CrossRef86
Hua Yang, Min Pu, David Rodriguez, Donald Underwood, Brian P Griffin, Vidyasagar Kalahasti, James D Thomas, Richard C Brunken. (2004) Ischemic and viable myocardium in patients with Non–Q-Wave or Q-Wave myocardial infarction and left ventricular dysfunction. Journal of the American College of Cardiology 43:4, 592-598
CrossRef87
Myung Ho Jeong. (2004) Percutaneous Coronary Intervention for Coronary Artery Disease. Journal of the Korean Medical Association 47:8, 736
CrossRef88
Christian W. Hamm, Paul G. Hugenholtz. (2003) Silicon carbide-coated stents in patients with acute coronary syndrome. Catheterization and Cardiovascular Interventions 60:3, 375-381
CrossRef89
R. Hodl, W. Klein. (2003) The role of low-molecular-weight heparins in cardiovascular medicine. Journal of Clinical Pharmacy and Therapeutics 28:5, 371-378
CrossRef90
J. Willis Hurst, Riccardo Bigi, Lauro Cortigiani, Alessandro Desideri. (2003) Exercise electrocardiography after acute coronary syndromes: Still the first testing modality?. Clinical Cardiology 26:8, 390-395
CrossRef91
Debabrata Mukherjee, Kim A. Eagle. (2003) Revised guidelines for the management of non-ST-segment elevation acute coronary syndromes. Current Cardiology Reports 5:4, 289-295
CrossRef92
William W O’Neill. (2003) “Watchful waiting”after thrombolysis. Journal of the American College of Cardiology 42:1, 17-19
CrossRef93
Peter Bogaty, James Brophy. (2003) Increasing burden of treatment in the acute coronary syndromes: is it justified?. The Lancet 361:9371, 1813-1816
CrossRef94
T. G. Lyras, V. A. Papapanagiotou, M. G. Foukarakis, F. K. Panou, N. D. Skampas, J. A. Lakoumentas, C. V. Priftis, A. A. Zacharoulis. (2003) Evaluation of serial QT dispersion in patients with first non-Q-wave myocardial infarction: Relation to the severity of underlying coronary artery disease. Clinical Cardiology 26:4, 189-195
CrossRef95
Nathan E. Green, James T. Maddux, J. E. B. Burchenal. (2003) Coronary angioplasty. Current Treatment Options in Cardiovascular Medicine 5:1, 13-24
CrossRef96
William E Boden, Carl J Pepine. (2003) Introduction to “optimizing management of non–ST-segment elevation acute coronary syndromes”. Journal of the American College of Cardiology 41:4, S1-S6
CrossRef97
Steven E Nissen. (2003) Pathobiology, not angiography, should guide managementin acute coronary syndrome/non–ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 41:4, S103-S112
CrossRef98
Christopher P Cannon. (2003) Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes. Journal of the American College of Cardiology 41:4, S43-S48
CrossRef99
William E Boden. (2003) “Routine invasive” versus “selective invasive” approaches to non–ST-segment elevation acute coronary syndromes management in the post-stent/platelet inhibition era. Journal of the American College of Cardiology 41:4, S113-S122
CrossRef100
Raymond G. McKay. (2003) “Ischemia-guided” versus “early invasive” strategies in the management of acute coronary syndrome/non–ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 41:4, S96-S102
CrossRef101
Sachin M. Navare, Athanasios Kapetanopoulos, Gary V. Heller. (2003) Pharmacologic radionuclide myocardial perfusion imaging. Current Cardiology Reports 5:1, 16-24
CrossRef102
B.o Lagerqvist, Steen Husted, Fredrik Kontny, Ulf Näslund, Elisabeth Ståhle, Eva Swahn, Lars Wallentin. (2002) A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. Journal of the American College of Cardiology 40:11, 1902-1914
CrossRef103
Christoph Pechlaner, Christian J Wiedermann. (2002) The RITA 3 trial. The Lancet 360:9349, 1971
CrossRef104
Nasser Lakkis, Valeri Tsyboulev, Michael C. Gibson, Sabina A. Murphy, William S. Weintraub, Peter M. DiBattiste, Christopher P. Cannon. (2002) Outcome of Patients With Acute Coronary Syndrome Admitted to Hospitals With or Without Onsite Cardiac Catheterization Laboratory. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:4, 232-237
CrossRef105
Ravi K Yarlagadda, William E Boden. (2002) Cardioprotective effects of an early invasive strategy for non–ST-segment elevationacute coronary syndromes. Journal of the American College of Cardiology 40:11, 1915-1918
CrossRef106
William E Boden. (2002) Reply. Journal of the American College of Cardiology 40:12, 2205-2206
CrossRef107
KS Brar. (2002) Stents in acute non-Q wave myocardial infarction. Medical Journal Armed Forces India 58:4, 363-364
CrossRef108
KAA Fox, PA Poole-Wilson, RA Henderson, TC Clayton, DA Chamberlain, TRD Shaw, DJ Wheatley, SJ Pocock. (2002) Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. The Lancet 360:9335, 743-751
CrossRef109
Henock Saint-Jacques, Robert A. Harrington. (2002) Glycoprotein receptor inhibitors in the management of acute coronary syndromes. Current Cardiology Reports 4:4, 301-312
CrossRef110
David E. Kandzari, Robert M. Califf. (2002) TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. Current Opinion in Cardiology 17:4, 332-339
CrossRef111
William E. Boden. (2002) The role of pharmacotherapy and catheter-based intervention in the management of patients with non-st-segment elevation acute coronary syndromes. Current Cardiology Reports 4:4, 260-271
CrossRef112
Martin J. Quinn, Sorin J. Brener. (2002) Early invasive strategies for acute coronary syndromes. Current Cardiology Reports 4:4, 334-340
CrossRef113
Richard A. Deyo. (2002) C
ASCADE EFFECTS OF MEDICAL TECHNOLOGY . Annual Review of Public Health 23:1, 23-44
CrossRef114
Richard A Kerensky, Michael Wade, Prakash Deedwania, William E Boden, Carl J Pepine. (2002) Revisiting the culprit lesion in non–Q-wave myocardial infarction. Journal of the American College of Cardiology 39:9, 1456-1463
CrossRef115
Abhinav Goyal, Frederick F. Samaha, William E. Boden, Michael J. Wade, Stephen E. Kimmel. (2002) Stress test criteria used in the conservative arm of the frisc-ii trial underdetects surgical coronary artery disease whenapplied to patients in the vanqwish trial. Journal of the American College of Cardiology 39:10, 1601-1607
CrossRef116
Ulf Stenestrand, Lars Wallentin. (2002) Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study. The Lancet 359:9320, 1805-1811
CrossRef117
Christopher P. Cannon. (2002) Critical Pathway for Unstable Angina and Non-ST Elevation Myocardial Infarction. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:1, 12-21
CrossRef118
Daniel H. Solomon, David A. Ganz, Jerry Avorn, Robert J. Glynn, Eric L. Knight, C.Michael Gibson, Peter H. Stone. (2002) Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy. Journal of Clinical Epidemiology 55:2, 121-128
CrossRef119
Brendan P Phibbs, Frank I Marcus. (2002) Perpetuation of the myth of the Q-wave versus the non–Q-wave myocardial infarction. Journal of the American College of Cardiology 39:3, 556-557
CrossRef120
Ganesh Manoharan, A. A. Adgey. (2002) Current Management of Unstable Angina. American Journal of Cardiovascular Drugs 2:4, 237-243
CrossRef121
Marc Cohen. (2002) Combination of Low Molecular Weight Heparins with Antiplatelet Agents in Non-ST Elevation Acute Coronary Syndromes. Drugs 62:12, 1755-1770
CrossRef122
Thuraia Nageh, Roy A. Sherwood, Beverley M. Harris, Martyn R. Thomas. (2002) Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes. Catheterization and Cardiovascular Interventions 55:1, 37-42
CrossRef123
K. M. Detre, R. Holubkov. (2002) Coronary Revascularization on Balance: Robert L. Frye Lecture. Mayo Clinic Proceedings 77:1, 72-82
CrossRef124
Vladimir Birjiniuk. (2001) Patient outcomes in the assessment of myocardial injury following cardiac surgery. The Annals of Thoracic Surgery 72:6, S2208-S2212
CrossRef125
Raymond G. McKay, William E. Boden. (2001) Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non–ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Current Opinion in Cardiology 16:6, 364-369
CrossRef126
Donald D. Tresch, Haritha R. Alla. (2001) Diagnosis and Management of Myocardial Ischemia (Angina) in the Elderly Patient. The American Journal of Geriatric Cardiology 10:6, 337-344
CrossRef127
D Himbert. (2001) L'angor instable du sujet âgé. Annales de Cardiologie et d'Angéiologie 50:7-8, 397-403
CrossRef128
William E. Boden. (2001) Clinical trials. Current Opinion in Cardiology 16:6, 361-363
CrossRef129
Y Louvard. (2001) Traitement de l'angor instable : la stratégie invasive précoce. Annales de Cardiologie et d'Angéiologie 50:7-8, 385-396
CrossRef130
K Boughalem, J.Y Pagny, T Demichéli, N Danchin. (2001) Les inhibiteurs de la glycoprotéine IIb IIIa dans l'angor instable. Annales de Cardiologie et d'Angéiologie 50:7-8, 377-384
CrossRef131
William E. Boden. (2001) Defining the optimal pharmacotherapy of non–ST-segment elevation (NSTE) acute coronary syndromes (ACS): a rapidly moving target. Current Opinion in Cardiology 16:6, 370-374
CrossRef132
Daniel H Solomon, Peter H Stone, Robert J Glynn, David A Ganz, C.Michael Gibson, Russell Tracy, Jerry Avorn. (2001) Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. Journal of the American College of Cardiology 38:4, 969-976
CrossRef133
William G Kussmaul. (2001) Should we catheterize all patients with unstable angina? No—only the ones with coronary artery disease. Journal of the American College of Cardiology 38:4, 977-978
CrossRef134
David J. Harnick, David A. Vorchheimer. (2001) Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?. Current Cardiology Reports 3:5, 355-361
CrossRef135
Bronislaw Bednarz, Robert Wolk, Tomasz Mazurek, Sebastian Stec, Tomasz Chamiec. (2001) Event-free survival in patients after an acute coronary event with exercise-induced normalization of the T-wave. Clinical Cardiology 24:8, 564-569
CrossRef136
A. Scott Mathis, Parag Meswani, Sarah A. Spinler. (2001) Risk Stratification in Non-ST Segment Elevation Acute Coronary Syndromes with Special Focus on Recent Guidelines. Pharmacotherapy 21:8, 954-987
CrossRef137
Robert Fromm, Denise Meyer, Gabriel Habib, Robert Roberts, Janice Zimmerman, Ann Boudreaux, Richard Smalling, Chuan-Chuan C. Wun, Barry Davis. (2001) A double-blind, multicentered study comparing the accuracy of diagnostic markers to predict short- and long-term clinical events and their utility in patients presenting with chest pain. Clinical Cardiology 24:7, 516-520
CrossRef138
Elliot Rapaport. (2001) Guidelines for the acute coronary syndromes. Current Cardiology Reports 3:4, 289-296
CrossRef139
JS Dugal, MK Garg, M Sashi Kumar. (2001) Stent in acute non-Q wave myocardial infarction. Medical Journal Armed Forces India 57:3, 254-255
CrossRef140
Cannon, Christopher P., Weintraub, William S., Demopoulos, Laura A., Vicari, Ralph, Frey, Martin J., Lakkis, Nasser, Neumann, Franz-Josef, Robertson, Debbie H., DeLucca, Paul T., DiBattiste, Peter M., Gibson, C. Michael, Braunwald, Eugene, . (2001) Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban. New England Journal of Medicine 344:25, 1879-1887
Full Text141
Boden, William E., McKay, Raymond G., . (2001) Optimal Treatment of Acute Coronary Syndromes — An Evolving Strategy. New England Journal of Medicine 344:25, 1939-1942
Full Text142
Verghese Mathew, Michael Farkouh, Diane E Grill, Lynn H Urban, Jack T Cusma, Guy S Reeder, David R Holmes, Bernard J Gersh. (2001) Clinical risk stratification correlates with the angiographic extent of coronary artery disease in unstable angina. Journal of the American College of Cardiology 37:8, 2053-2058
CrossRef143
Sidney C. Smith, James T. Dove, Alice K. Jacobs, J. Ward Kennedy, Dean Kereiakes, Morton J. Kern, Richard E. Kuntz, Jeffery J. Popma, Hartzell V. Schaff, David O. Williams, Raymond J. Gibbons, Joseph P. Alpert, Kim A. Eagle, David P. Faxon, Valentin Fuster, Timothy J. Gardner, Gabriel Gregoratos, Richard O. Russell, Sidney C. Smith. (2001) ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). Journal of the American College of Cardiology 37:8, 2239
CrossRef144
Joseph S. Alpert. (2001) Differences in outcome between percutaneous coronary intervention and coronary bypass grafting. Current Cardiology Reports 3:3, 173-174
CrossRef145
Edward Guadagnoli, Mary Beth Landrum, Sharon-Lise T. Normand, John Z. Ayanian, Pushkal Garg, Paul J. Hauptman, Thomas J. Ryan, Barbara J. McNeil. (2001) Impact of Underuse, Overuse, and Discretionary Use on Geographic Variation in the Use of Coronary Angiography After Acute Myocardial Infarction. Medical Care 39:5, 446-458
CrossRef146
R KELLY. (2001) NEW DEVELOPMENTS IN PERCUTANEOUS CORONARY INTERVENTION. Critical Care Clinics 17:2, 303-320
CrossRef147
F ALMEDA, R SNELL, J PARRILLO. (2001) The Contemporary Management of Acute Myocardial Infarction. Critical Care Clinics 17:2, 411-434
CrossRef148
Wayne L. Miller, Guy S. Reeder. (2001) Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. Mayo Clinic Proceedings 76:4, 391-405
CrossRef149
W L Miller, G S Reeder. (2001) Adjunctive therapies in the treatment of acute coronary syndromes.. Mayo Clinic Proceedings 76:4, 391-405
CrossRef150
William H. Frishman. (2001) Management of Unstable Angina in 2001. Heart Disease71-72
CrossRef151
Erdal Cavusoglu, Samin K. Sharma, William Frishman. (2001) Unstable Angina Pectoris and Non-Q-Wave Myocardial Infarction. Heart Disease116-130
CrossRef152
Frederic Kontny. (2001) Improving outcomes in acute coronary syndromes-The FRISCII trial. Clinical Cardiology 24:S1, 3-7
CrossRef153
Adam B Greenbaum, Robert A Harrington, Michael P Hudson, Cynthia M MacAulay, Robert G Wilcox, Maarten L Simoons, Lisa G Berdan, Alan Guerci, Dennis V Cokkinos, Michael M Kitt, A.Michael Lincoff, Eric J Topol, Robert M Califf, E.Magnus Ohman. (2001) Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. Journal of the American College of Cardiology 37:2, 492-498
CrossRef154
(2001) Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. Journal of the American College of Cardiology 37:2, 475-484
CrossRef155
Martin Möckel, Willie Gerhardt, Günther Heller, Frank Klefisch, Oliver Danne, Jakob Maske, Christian Müller, Thomas Störk, Ulrich Frei, Alan H.B. Wu. (2001) Validation of NACB and IFCC guidelines for the use of cardiac markers for early diagnosis and risk assessment in patients with acute coronary syndromes. Clinica Chimica Acta 303:1-2, 167-179
CrossRef156
Alfredo Rodriguez, Victor Bernardi, Jose Navia, Julio Baldi, Liliana Grinfeld, Jorge Martinez, Daniel Vogel, Roberto Grinfeld, Alejandro Delacasa, Marcelo Garrido, Raul Oliveri, Eduardo Mele, Igor Palacios, William O’Neill. (2001) Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. Journal of the American College of Cardiology 37:1, 51-58
CrossRef157
Thomas P. Wharton, Nancy Sinclair McNamara. (2001) Management of Acute Coronary Syndromes in the Community Hospital Without Cardiac Surgical Capability. American Journal of Cardiovascular Drugs 1:5, 375-385
CrossRef158
Dennis V. Cokkinos. (2001) The Treatment of Coronary Heart Disease: An Update. Current Medical Research and Opinion 17:1, 38-40
CrossRef159
Bernard R Chaitman, Saad R Bitar. (2001) Is ST segment elevation non–Q- wave myocardial infarction after thrombolytic therapy a new clinical entity that requires an invasive management strategy?. Journal of the American College of Cardiology 37:1, 26-29
CrossRef160
James E Udelson. (2001) Testing our tests: surrogate end points versus driving patient management and outcomes. Journal of the American College of Cardiology 37:1, 89-92
CrossRef161
Thomas J Ryan. (2001) Present-day PTCR versus CABG: a randomized comparison with a different focus and a new result. Journal of the American College of Cardiology 37:1, 59-62
CrossRef162
Laura F. Wexler, Alvin S. Blaustein, Philip W. Lavori, Kenneth G. Lehmann, Michael Wade, William E. Boden. (2001) Non–Q-wave myocardial infarction following thrombolytic therapy: a comparison of outcomes in patients randomized to invasive or conservative post-infarct assessment strategies in the Veterans Affairs Non–Q-Wave Infarction Strategies In-Hospital (VANQWISH) trial. Journal of the American College of Cardiology 37:1, 19-25
CrossRef163
Dhanunjaya Lakkireddy, Manohar S. Gowda, James L. Vacek, Dave Hallas. (2000) The role of angioplasty for non-Q wave myocardial infarction: The impact of diabetes on outcomes. Comprehensive Therapy 26:4, 269-275
CrossRef164
William J. Rogers, John G. Canto, Costas T. Lambrew, Alan J. Tiefenbrunn, Becky Kinkaid, David A. Shoultz, Paul D. Frederick, Nathan Every. (2000) Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999. Journal of the American College of Cardiology 36:7, 2056-2063
CrossRef165
James E Calvin, Lloyd W Klein, Elizabeth J VandenBerg, Peter Meyer, Joseph E Parrillo. (2000) Validated risk stratification model accurately predicts low risk in patients with unstable angina. Journal of the American College of Cardiology 36:6, 1803-1808
CrossRef166
Cheuk-Kit Wong, Harvey D. White. (2000) Medical treatment for acute coronary syndromes. Current Opinion in Cardiology 15:6, 441-462
CrossRef167
T. NAKATA, T. KOBAYASHI, N. TAMAKI, H. KOBAYASHI, T. WAKABAYASHI, S. SHIMOSHIGE, K. OH-HORI, K. HAMABE, K. HIRASAWA, T. MATSUKI, T. SHOGASE, M. FURUDATE, K. SHIMAMOTO. (2000) Prognostic value of impaired myocardial fatty acid uptake in patients with acute myocardial infarction. Nuclear Medicine Communications 21:10, 897-906
CrossRef168
George A. Stouffer, Lorren Mott, Alberto Brizolara, Vijay Subbarao. (2000) Left main coronary artery disease in adults younger than 50 years: A comparison with older patients. Catheterization and Cardiovascular Interventions 51:1, 11-17
CrossRef169
Michele Galli, Diego Ardissino. (2000) Early non-invasive management of acute coronary syndromes. The Lancet 356:9233, 941-942
CrossRef170
Philip W Lavori, Ree Dawson, A.John Rush. (2000) Flexible treatment strategies in chronic disease: clinical and research implications. Biological Psychiatry 48:6, 605-614
CrossRef171
Mandeep Singh, Charanjit S Rihal, Peter B Berger, Malcolm R Bell, Diane E Grill, Kirk N Garratt, Gregory W Barseness, David R Holmes. (2000) Improving outcome over time of percutaneous coronary interventions in unstable angina. Journal of the American College of Cardiology 36:3, 674-678
CrossRef172
Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, David P Faxon, Valentin Fuster, Timothy J Gardner, Gabriel Gregoratos, Richard O Russell, Sidney C Smith. (2000) ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction. Journal of the American College of Cardiology 36:3, 970-1062
CrossRef173
(2000) Part 7: The Era of Reperfusion. Resuscitation 46:1-3, 203-237
CrossRef174
Charles L. Baird, Scott E. Crater. (2000) Medical management of significant coronary angiographic stenoses: Outcome of 60 patients observed for 433 patient years. Clinical Cardiology 23:8, 591-594
CrossRef175
Lars Wallentin, Bo Lagerqvist, Steen Husted, Frederic Kontny, Elisabet Ståhle, Eva Swahn. (2000) Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. The Lancet 356:9223, 9-16
CrossRef176
Hé;ctor Bueno. (2000) Early Prognostic Assessment and Treatment of Acute Myocardial Infarction in the Elderly. The American Journal of Geriatric Cardiology 9:4, 192-196
CrossRef177
Gary E. Lane, David R. Holmes. (2000) Primary angioplasty for acute myocardial infarction in the elderly. Coronary Artery Disease 11:4, 305-313
CrossRef178
Herbert Hirsch, Jason Lazar, Kevin P. Marzo, Richard M. Steingart. (2000) Percutaneous revascularization for unstable angina in the elderly. Coronary Artery Disease 11:4, 315-322
CrossRef179
William E Boden, Wiek H van Gilst, Rudy G Scheldewaert, Ian R Starkey, Marc F Carlier, Desmond G Julian, Anne Whitehead, Michel E Bertrand, Jacques J Col, Ole Lederballe Pedersen, Kong I Lie, Jean-P Santoni, Kim M Fox. (2000) Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. The Lancet 355:9217, 1751-1756
CrossRef180
Haffner, Steven M., . (2000) Coronary Heart Disease in Patients with Diabetes. New England Journal of Medicine 342:14, 1040-1042
Full Text181
Francine K Welty. (2000) Optimal management of non–ST segment elevation myocardial infarction remains unclear. Journal of the American College of Cardiology 35:4, 903-906
CrossRef182
Martin Möckel, Günther Heller, Katrin Berg, Frank-Rainer Klefisch, Oliver Danne, Christian Müller, Thomas V Störk, Ulrich Frei, Alan H.B Wu. (2000) The acute coronary syndrome diagnosis and prognostic evaluation by troponin I is influenced by the test system affinity to different troponin complexes. Clinica Chimica Acta 293:1-2, 139-155
CrossRef183
Grant S Scull, Jenny S Martin, W.Douglas Weaver, Nathan R Every. (2000) Early angiography versus conservative treatment in patients with non–ST elevation acute myocardial infarction. Journal of the American College of Cardiology 35:4, 895-902
CrossRef184
Sudhir S. Kushwaha, John A. Ambrose. (2000) Does ischemic preconditioning limit infarct size in non-Q-wave myocardial infarction?. Coronary Artery Disease 11:2, 191-194
CrossRef185
William J Rogers, John G Canto, Hal V Barron, Joseph A Boscarino, David A Shoultz, Nathan R Every. (2000) Treatment and outcome of myocardial infarction in hospitals with and without invasive capability. Journal of the American College of Cardiology 35:2, 371-379
CrossRef186
GEORGE BRIASSOULIS, PANAJIOTIS KALABALIKIS, VASILIS THANOPOULOS, TASSOS HATZIS. (2000) Non-Q wave acute myocardial infarction in acute meningococcemia in a 10-year-old girl. Pediatric Emergency Care 16:1, 33-38
CrossRef187
M. Bilal Murad, Timothy D. Henry. (2000) Unstable angina. Current Treatment Options in Cardiovascular Medicine 2:1, 37-53
CrossRef188
John Coppola, John A. Ambrose. (2000) Non-Q-Wave myocardial infarction. Current Treatment Options in Cardiovascular Medicine 2:1, 19-26
CrossRef189
Madhu K Natarajan, Shamir Mehta, Salim Yusuf. (2000) Management of myocardial infarction: looking beyond efficacy. Journal of the American College of Cardiology 35:2, 380-381
CrossRef190
Yeghiazarians, Yerem, Braunstein, Joel B., Askari, Arman, Stone, Peter H., . (2000) Unstable Angina Pectoris. New England Journal of Medicine 342:2, 101-114
Full Text191
Dennis Goodman. (2000) Early-invasive or early-conservative management of patients with unstable angina or non-Q-wave myocardial infarction. Advances in Therapy 17:1, 45-55
CrossRef192
Frederic Kontny. (2000) Acute management-How should we intervene?. Clinical Cardiology 23:S1, 8-12
CrossRef193
Lars Wallentin. (2000) Implications of the FRISCII Trial: Initial Medical Stabilization Followed by an Early Invasive Approach is the Preferred Strategy in Unstable Coronary Syndromes. Scandinavian Cardiovascular Journal 34:1, 4-6
CrossRef194
C. Richard Conti. (2000) Optimal therapeutic management of Non-Q-Wave myocardial infarctions. Clinical Cardiology 23:1, 1-3
CrossRef195
Rankin, James M., Spinelli, John J., Carere, Ronald G., Ricci, Donald R., Penn, Ian M., Hilton, J. David, Henderson, Mark A., Hayden, Robert I., Buller, Christopher E., . (1999) Improved Clinical Outcome after Widespread Use of Coronary-Artery Stenting in Canada. New England Journal of Medicine 341:26, 1957-1965
Full Text196
Lorren Mott Alberto Brizolara, &NA; Charles McCreery George A. Stouffer, Marschall S. Runge, George A. Stouffer, Richard G. Sheahan. (1999) Cardiology Grand Rounds from The University of Texas Medical Branch. The American Journal of the Medical Sciences 318:6, 406
CrossRef197
Josep Lupón, Vicente Valle, Jaume Marrugat, Roberto Elosua, Lluis Serés, Marco Pavesi, Román Freixa, Ginés Sanz, Rafel Masiá, Lluis Molina, Joan Sala, Jordi Serra. (1999) Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. Journal of the American College of Cardiology 34:7, 1947-1953
CrossRef198
Shmuel Fuchs, Ran Kornowski, Roxana Mehran, Lowell F Satler, Augusto D Pichard, Kenneth M Kent, Mun K Hong, Steve Slack, Gregg W Stone, Martin B Leon. (1999) Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes. Journal of the American College of Cardiology 34:6, 1704-1710
CrossRef199
Alter, David A., Naylor, C. David, Austin, Peter, Tu, Jack V., . (1999) Effects of Socioeconomic Status on Access to Invasive Cardiac Procedures and on Mortality after Acute Myocardial Infarction. New England Journal of Medicine 341:18, 1359-1367
Full Text200
Dennis V. Cokkinos. (1999) The continuously evolving problems of acute ischemic coronary syndromes. Clinical Cardiology 22:10, 609-610
CrossRef201
Thaddeus R. Tolleson, Robert A. Harrington. (1999) Recent clinical trials in acute coronary syndromes without persistent ST elevation. Current Opinion in Cardiology 14:5, 403
CrossRef202
Thomas J Ryan, Elliott M Antman, Neil H Brooks, Robert M Califf, L.David Hillis, Loren F Hiratzka, Elliot Rapaport, Barbara Riegel, Richard O Russell, Earl E Smith, W.Douglas Weaver, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, Timothy J Gardner, Arthur Garson, Gabriel Gregoratos, Richard O Russell, Thomas J Ryan, Sidney C Smith. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 34:3, 890-911
CrossRef203
Alessandro Desideri, Riccardo Bigi, Gian Leone Suzzi, Claudio Coletta, Dario Gregori, Gino Valente, Paolo Fioretti. (1999) Stress echocardiography and exercise electrocardiography for risk stratification after non–Q-wave uncomplicated myocardial infarction. The American Journal of Cardiology 84:6, 739-741
CrossRef204
Sasan Ghaffari. (1999) DETECTION AND MANAGEMENT OF CORONARY ARTERY DISEASE IN PATIENTS WITH RHEUMATOLOGIC DISORDERS. Rheumatic Disease Clinics of North America 25:3, 657-668
CrossRef205
Harald Darius. (1999) Role of Nitrates for the Therapy of Coronary Artery Disease Patients in the Years beyond 2000. Journal of Cardiovascular Pharmacology 34:Supplement 2, S15-S20
CrossRef206
Christopher P. Cannon. (1999) Incorporating platelet glycoprotein iib/iiia inhibition in critical pathways: Unstable angina/non-st-segment elevation myocardial infarction. Clinical Cardiology 22:S4, 30-36
CrossRef207
J-J Goy. (1999) Contemporary approach to management of unstable angina. The Lancet 354:9180, 694-695
CrossRef208
(1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. The Lancet 354:9180, 708-715
CrossRef209
Harald Darius. (1999) Role of Nitrates for the Therapy of Coronary Artery Disease Patients in the Years beyond 2000. Journal of Cardiovascular Pharmacology 34, S15-S20
CrossRef210
Jacob Joseph, Jorge Saucedo, J. David Talley. (1999) Progress in Interventional Cardiology. Journal of Interventional Cardiology 12:4, 321-324
CrossRef211
M Schwaiger, J Melin. (1999) Cardiological applications of nuclear medicine. The Lancet 354:9179, 661-666
CrossRef212
Schwartz, Lisa M., Woloshin, Steven, Welch, H. Gilbert, . (1999) Misunderstandings about the Effects of Race and Sex on Physicians' Referrals for Cardiac Catheterization. New England Journal of Medicine 341:4, 279-283
Full Text213
Wayne B Batchelor, Eric D Peterson, Daniel B Mark, J.David Knight, Christopher B Granger, Paul W Armstrong, Robert M Califf. (1999) A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. Journal of the American College of Cardiology 34:1, 12-19
CrossRef214
John C. Rutledge, Dianne A. Hyson, Debbie Garduno, Douglas A. Cort, Linda Paumer, C. Tissa Kappagoda. (1999) Lifestyle Modification Program in Management of Patients With Coronary Artery Disease: The Clinical Experience in a Tertiary Care Hospital. Journal of Cardiopulmonary Rehabilitation 19:4, 226-234
CrossRef215
Greg C. Flaker, J.Wayne Warnica, Frank M. Sacks, Lemuel A. Moyé, Barry R. Davis, Jean L. Rouleau, Richard R. Webel, Marc A. Pfeffer, Eugene Braunwald. (1999) Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Journal of the American College of Cardiology 34:1, 106-112
CrossRef216
Shmuel Gottlieb, Valentina Boyko, David Harpaz, Hanoch Hod, Miriam Cohen, Lori Mandelzweig, Zahi Khoury, Shlomo Stern, Solomon Behar. (1999) Long-term (three-year) prognosis of patients treated with reperfusion or conservatively after acute myocardial infarction. Journal of the American College of Cardiology 34:1, 70-82
CrossRef217
Patrick J Scanlon, David P Faxon, Anne-Marie Audet, Blase Carabello, Gregory J Dehmer, Kim A Eagle, Ronald D Legako, Donald F Leon, John A Murray, Steven E Nissen, Carl J Pepine, Rita M Watson, James L Ritchie, Raymond J Gibbons, Melvin D Cheitlin, Kim A Eagle, Timothy J Gardner, Arthur Garson, Richard O Russell, Thomas J Ryan, Sidney C Smith. (1999) ACC/AHA guidelines for coronary angiography. Journal of the American College of Cardiology 33:6, 1756-1824
CrossRef218
J.J.P. Kastelein. (1999) The future of best practice. Atherosclerosis 143, S17-S21
CrossRef219
J. DAVID TALLEY. (1999) Interventional Management of Acute Coronary Syndromes. Journal of Interventional Cardiology 12:2, 117-132
CrossRef220
J Mahmarian. (1999) Management decisions in survivors of acute myocardial infarction using radionuclide imaging. ACC Current Journal Review 8:2, 50-56
CrossRef221
Stephen M Zaacks, Philip R Liebson, James E Calvin, Joseph E Parrillo, Lloyd W Klein. (1999) Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?. Journal of the American College of Cardiology 33:1, 107-118
CrossRef222
Mahomed Y Salame, Ranjit S More, Stefan Verheye, Mark E Leimbach, Spencer B King III, Nicolas AF Chronos. (1999) The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. Acute Cardiac Care 2:4, 207-215
CrossRef223
(1998) Management of Non–Q-Wave Myocardial Infarction. New England Journal of Medicine 339:19, 1395-1398
Full Text224
Salim Yusuf. (1998) Variations between countries in invasive cardiac procedures. The Lancet 352:9138, 1470
CrossRef225
RA Henderson, DA Chamberlain. (1998) Variations between countries in invasive cardiac procedures. The Lancet 352:9138, 1469-1470
CrossRef226
Eric J Topol. (1998) What role for catheter laboratories in unstable angina?. The Lancet 352:9127, 500-501
CrossRef227
Jorge Saucedo, J. David Talley. (1998) Progress in Interventional Cardiology. Journal of Interventional Cardiology 11:4, 393-396
CrossRef228
Lange, Richard A., Hillis, L. David, . (1998) Use and Overuse of Angiography and Revascularization for Acute Coronary Syndromes. New England Journal of Medicine 338:25, 1838-1839
Full Text
- Letters
